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doi:10.1Objective: The decline in normalized forced 1-second expiratory volume after lung transplantation is inevita-
ble; however, the effect of this change on survival is unknown. Additionally, the benefit of double versus single
lung transplant is debated, particularly because pulmonary function is only slightly better after double lung
transplant. Our goal was to determine the effect of the temporal pattern of post-transplant forced 1-second ex-
piratory volume (percentage of predicted) on the risk of death after transplant and the differences in the sensi-
tivity of single and double lung transplant to this relationship.
Methods: From February 1990 to January 2008, 622 adults underwent lung transplantation, of whom 315 (51%)
received 2 lungs. Of the 509 patients (82%) with available data, 9471 longitudinal evaluations of forced
1-second expiratory volume (percentage of predicted) were analyzed. The temporal pattern was characterized
for each patient, and the resulting curvewas evaluated as a time-varying covariable function in the survival anal-
ysis. Differences in sensitivity of single and double lung transplant were assessed by interaction.
Results: Forced 1-second expiratory volume (percentage of predicted) increased from 50% immediately post-
operatively to 55% at 1 year after single lung transplant and then gradually declined to 47% by 3 years. Al-
though the pattern was similar after double lung transplant, the corresponding forced 1-second expiratory
volume (percentage of predicted) at these points was greater—60%, 75%, and 65%. Lower post-transplant
forced 1-second expiratory volume (percentage of predicted) was associated with a substantially increased
risk of death after single lung transplant (P<.0001); however, this increase was far less after double lung trans-
plant (P<.0001).
Conclusions: The results of our study have demonstrated the effect of changing lung function after lung trans-
plantation on survival. Survival after single lung transplant proved more sensitive to declining pulmonary func-
tion, demonstrating an advantage of the increased pulmonary reserve provided by double lung transplant. (J
Thorac Cardiovasc Surg 2012;144:197-203)T
XSupplemental material is available online.
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The Journal of Thoracic and Casurvival after lung transplantation. This is largely because
FEV1% and survival are simultaneously evolving out-
comes, and statistical methods to analyze the effect of 1 out-
come on another are extremely limited. Although some
survival advantage has been demonstrated for double lung
transplant over single lung transplant for emphysema and
arguably for other transplant indications, post-transplant
spirometry is only modestly better.1-4 Nonetheless, it has
been speculated that the putative survival advantage of
double over single lung transplant is secondary to
increased post-transplant FEV1%. Our goal was to deter-
mine the effect of the temporal pattern of post–lung trans-
plant FEV1% on the risk of death after transplant and the
differences in the sensitivity of single and double lung trans-
plant to this relationship. For this, we examined spirometry
from multiple longitudinal pulmonary function tests to as-
sess temporal trend and developed a novel statistical
method to evaluate its effect on survival.METHODS
Patients
From February 1990 to January 2008, 622 patients older than 18 years
underwent primary lung transplantation for end-stage lung disease atrdiovascular Surgery c Volume 144, Number 1 197
Abbreviations and Acronyms
BOS ¼ bronchiolitis obliterans syndrome
FEV1% ¼ forced 1-second expiratory volume,
percentage of predicted
CL ¼ confidence limit
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XCleveland Clinic, exclusive of heart–lung transplantation. The recipient,
donor, and surgical data were extracted from the Unified Transplant Data-
base and Electronic Data Interface for Transplantation. Themean age of the
patients at transplantationwas 49 13 years, and 53%were men (Table 1).
Spirometry
The results of spirometry performed in the Cleveland Clinic’s certified
pulmonary function laboratory, which conforms to the standards of the
American Thoracic Society, were retrieved from the Pulmonary Function
Test database. These included the National Health and Nutrition Examina-
tion Survey–normalized postoperative FEV1%.5,6 A total of 9471
postoperative values were available for 509 patients (82% of total
population; Figure E1). Patients who died before these tests were per-
formed or whose records could not be located were excluded (18%).
Nearly one half (52/113) of these patients underwent transplantation
from 1990 through 1994. During that time, the median interval to the first
spirometry assessment was 2.7 years. Of the 52 patients, the median inter-
val to death was 0.94 year, well before lung function would have been as-
sessed. In subsequent years, the median interval to the first spirometry
assessment was shortly after transplantation (2.5 weeks), and the median
interval to death among those not undergoing spirometry was just longer
than 1 month. Thus, the predominant reason for not having spirometry
data was that the patients were too ill and often died. The Cleveland Clinic
protocol for spirometry is now 3 weeks, 3 months, and every 3 months after
transplantation and when clinically indicated. All databases used for the
present study were approved for use in research by the institutional review
board, with patient consent waived.
End Points
The primary end point in the present study was all-cause mortality. Me-
dian follow-up for vital status was 2.7 years from transplant, and 1817
patient-years of data were available for analysis. Twenty-five percent of
survivors were followed up for more than 5 years and 10% for more
than 8 years.
Statistical Analysis
The focus of the present data analysis was twofold: (1) to determine the
influence of National Health and Nutrition Examination Survey–
normalized postoperative FEV1% on mortality after lung transplantation,
and (2) to test the sensitivity of time-related instantaneous risk of death to
FEV1% in single versus double lung transplant.
We considered postoperative FEV1% as a time-varying covariable to
assess its influence on survival after transplantation. However, because
the postoperative FEV1% changes over time and is quantified with mea-
surement error, we used the following novel 2-step approach to the analy-
sis: first, to estimate the individual patient trajectory of FEV1% over time;
and second, to use the collection of these patient-specific trajectories as
time-varying covariables in a model of the instantaneous risk of death.
Appendix E1 provides a more detailed description of these 2 steps, which
are summarized as follows.
Step 1: Patient-specific trajectory. We assumed that each pa-
tient’s FEV1% trajectory over time takes the shape of a smooth curve
and that the observed zigzag FEV1% pattern is a result of an underlying198 The Journal of Thoracic and Cardiovascular Surg‘‘true’’ FEV1% trajectory and measurement error. We estimated the
patient-specific FEV1% trajectory by fitting each patient’s FEV1% mea-
surements with a penalized spline if more than 12 measurements were
available (324 patients, 64%).7 If a patient had no more than 2 FEV1%
measurements, the trajectory was assumed to be a horizontal line over
time (21 patients [4%], 76% of whom died before the next scheduled spi-
rometry). If a patient had between 3 and 12 FEV1% measurements, we
used a straight-line fit instead of a penalized spline (164 patients [32%]),
because the latter requires a larger sample size.
These patient-specific curves were used as continuous so-called time-
varying covariables as described in Step 2. In addition, they were averaged
to obtain an overall mean curve for post-transplant FEV1% and separate
mean curves for single and double lung transplant groups.
Step 2: Instantaneous risk of death after transplant. The
hazard function for death was estimated by a multiphase hazard model.8
Multivariable analysis was performed in the multiphase hazard function
domain.
We first identified preoperative and intraoperative risk factors for death
as follows: Using the variables listed in Appendix E2, we performed vari-
able selection by bagging (bootstrap aggregation), consisting of automated
forward stepwise variable selection, with a P value criterion for retention of
variables in the model of .05, and 500 bootstrap samples.9,10 The frequency
of occurrence of variables in each of the 500 models was ascertained and
indicated their reliability (aggregation step). The variables with bootstrap
reliability of 50% or greater were retained in the analysis.
Once we obtained a multivariable model with preoperative and intrao-
perative risk factors for death, we forced the patient-specific FEV1% tra-
jectories into the model as a time-varying covariable function. In addition,
a propensity score, using all variables in Appendix E2 except for the max-
imum ischemic time, was developed using logistic regression analysis and
was forced into the survival model. This adjusted for differences in patient
characteristics between those receiving single versus double lung trans-
plantation (Figures E2 and E3).
Presentation. Simple descriptive statistics were used to summarize
the data. Continuous variables are presented as the mean  standard devi-
ation or as 15th, 50th (median), and 85th percentiles when the data were
skewed. Categorical data are described using frequencies and percentages.
Comparisons were made using the chi-square test. All analyses were per-
formed using SAS, version 9.1 (SAS Institute, Cary, NC). Uncertainty
was expressed by confidence limits (CLs) equivalent to 1 standard error
(68%).RESULTS
FEV1% and Single Versus Double Lung Transplant
FEV1% steadily increased after single lung transplant
and peaked at 55% at 1 year and then gradually declined
to 47% by 3 years; although the pattern was similar after
double lung transplant, FEV1% at these points was
greater—75% and 65% at 1 and 3 years, respectively
(Figure 1). Survival after single lung transplant was 99%,
88%, 68%, and 53% at 30 days and 1, 3, and 5 years, re-
spectively. The hazard function was constant at 13% per
year (68% CL, 12%–14%). Survival after double lung
transplant was 99%, 91%, 77%, and 64% at 30 days and
1, 3, and 5 years, respectively (Figure 2). The hazard func-
tion was constant at 8.9% per year (68% CL, 7.9%–10%).
Lower post-transplant FEV1% was associated with a sub-
stantially increased risk of death after single lung transplant
(P<.0001; Figure 3, A), but this increase was far less after
double lung transplant (P<.0001; Table 2 and Figure 3, B).ery c July 2012
TABLE 1. Recipient, donor, and transplant details stratified by single versus double lung transplantation
Variable
Single lung transplant Double lung transplant
P valuePatients (n)* Value Patients (n)* Value
Recipient
Preoperative pulmonary function
FEV1 (% of predicted) 211 27  15 238 30  17 .04
FVC (% of predicted) 198 52  15 206 46  18 <.0001
FEV1/FVC 198 0.54  0.35 206 0.69  0.39 <.0001
Demographics
Age (y) 245 57  7.1 264 42  13 <.0001
Women 245 110 (45) 264 132 (50) .2
Race
White 245 236 (96) 264 236 (89) .003
Black 245 9 (3.7) 264 23 (8.7) .02
Body mass index (kg/m2) 245 25  4.6 264 24  5.7 .0009
Body surface area (m2) 245 1.8  0.24 264 1.8  0.29 .005
Indication for surgery
COPD/emphysema 245 148 (60) 264 54 (20) <.0001
a1-Antitrypsin deficiency 245 23 (9.4) 264 11 (4.2) .02
Cystic fibrosis 245 0 (0) 264 85 (32) <.0001
Bronchiectasis 245 0 (0) 264 11 (4.2) .001
Usual interstitial pneumonitis 245 50 (20) 264 46 (17) .4
Pulmonary arterial hypertension 245 2 (0.82) 264 16 (6.1) .001
Sarcoidosis 245 6 (2.4) 264 13 (4.9) .1
Eisenmenger syndrome 245 0 (0) 264 7 (2.7) .01
Comorbidities
Diabetes 219 22 (10) 237 56 (24) .0001
Serum creatinine (mg/dL) 196 0.72  0.22 225 0.74  0.29 .8
Serology/immunology
Blood type
A 245 103 (42) 264 107 (41) .7
AB 245 9 (3.7) 264 9 (3.4) .9
B 245 22 (9.0) 264 39 (15) .04
O 245 111 (45) 264 109 (41) .4
Rhþ 245 204 (83) 263 212 (81) .4
Donor
Demographics
Age (y) 241 38  15 258 35  15 .02
Women 242 117 (48) 259 138 (53) .3
Race (white) 242 218 (90) 260 208 (80) .002
Body mass index (kg/m2) 242 25  5.6 259 25  5.9 .9
Body surface area (m2) 242 1.9  0.28 259 1.8  0.27 .5
Comorbidities
Hypertension 219 42 (19) 227 40 (18) .7
Serum creatinine (mg/dL) 224 1.0  1.3 236 1.2  1.1 .03
Serology/immunology
Blood type
A 242 76 (31) 259 82 (32) 1.0
AB 242 1 (0.41) 259 3 (1.2) .3
B 242 16 (6.6) 259 36 (14) .008
O 242 149 (62) 259 138 (53) .06
Rhþ 238 201 (84) 254 215 (85) 1.0
Cause of death
Anoxia 245 13 (5.3) 264 19 (7.2) .4
Cerebral bleeding 245 78 (32) 264 42 (16) <.0001
(Continued)
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TABLE 1. Continued
Variable
Single lung transplant Double lung transplant
P valuePatients (n)* Value Patients (n)* Value
Central nervous system tumor 245 3 (1.2) 264 3 (1.1) .9
Stroke 245 54 (22) 264 67 (25) .4
Head trauma 245 87 (36) 264 115 (44) .06
Recipient–donor mismatch
Donor male, recipient male 242 107 (44) 259 103 (40) .3
Donor female, recipient female 242 90 (37) 259 111 (43) .2
Donor male, recipient female 242 18 (7.4) 259 18 (6.9) .8
Donor female, recipient male 242 27 (11) 259 27 (10) .8
Rh mismatch 242 34 (14) 261 40 (15) .7
Transplant
Single left-side transplant 245 122 (50)
Single right-side transplant 245 123 (50)
Data presented as mean  standard deviation or n (%). FEV1, Forced 1-second expiratory volume; FVC, forced vital capacity; COPD, chronic obstructive pulmonary disease.
*Patients with data available.
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XMore specifically, the risk of death after lung transplant was
increasingly elevated at lower pretransplant FEV1% in sin-
gle lung transplant, but was independent of pretransplant
FEV1% after double lung transplant (Table 2 and
Figure 3, C). In addition, the risk of death was associated
only to a small degree with the pattern of FEV1% after dou-
ble lung transplant, but was substantially more sensitive to
this pattern after single lung transplant.
When translated from the risk of death into the probabil-
ity of surviving for 5 years (Figure 4), for the range of
FEV1% observed with single lung transplantation, the
probability of survival ranged from 65% at FEV1 70% of
predicted to 30% at FEV1 20% of predicted. The probabil-
ity of surviving 5 years after double lung transplant was
nearly constant, ranging from about 65% to 70% for the
span of observed FEV1. This relationship suggests anDLTx
SLTx
FIGURE 1. Forced 1-second expiratory volume (FEV1% of predicted)
after lung transplantation for single (SLTx) versus double (DLTx) lung
transplant. Solid lines represent nonparametric estimates of mean spirom-
etry values across time. Symbols are actual grouped data, without regard to
repeated measurements, used as a crude verification of model fit.
200 The Journal of Thoracic and Cardiovascular Surgevident difference in mortality when FEV1 decreases to
less than about 50% to 60% of predicted.
The predominant modes of death after both single and
double lung transplant were respiratory failure, infection,
and cardiovascular (Table E1). Respiratory failure was
more common after single lung transplant (P ¼ .009).
DISCUSSION
Survival and postoperative allograft function (spirome-
try) are considered the 2 most important outcomes after
lung transplantation.11 FEV1% is the standard indicator
of pulmonary function after transplant because of the sim-
plicity of the test and ease of longitudinal follow-up.12 A re-
cipient’s FEV1% typically increases to a plateau in the first
postoperative year.3 A decline from an established baseline
is considered the hallmark feature of bronchiolitisDLTx
SLTx
(202)
(100)
(54)
(25)
(205)
(136)
(71)
(27)
FIGURE 2. Survival after lung transplantation stratified by single (SLTx)
and double (DLTx) lung transplant. Solid lines represent parametric estimates
of survival enclosed within 68% confidence bands equivalent to1 standard
error. Symbols represent each death positioned on a vertical axis using the
Kaplan-Meier estimator. Vertical bars are 68% confidence limits equivalent
to 1 standard error, and numbers in parentheses represent patients remain-
ing alive and traced.
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FIGURE 3. Forced 1-second expiratory volume (FEV1% of predicted)
after lung transplantation (dashed lines) and its influence on hazard of
death (solid lines). A, Single lung transplant, (B) double lung transplant,
and (C) single lung (black lines) and double lung (gray lines) transplant.
Only point estimates depicted.
TABLE 2. Incremental risk factors for death after lung
transplantation
Factor Coefficient ± SE P value
Older age* 0.77  0.28 .006
Bronchiectasis or cystic fibrosis 0.60  0.25 .02
Lower donor creatininey 0.26  0.12 .04
Single lung transplant 1.8  0.48 <.0001
Preoperative
Interaction: double lung transplant
and lower pretransplant FEV1%z
0.076  0.22 .7
Interaction: single lung transplant
and lower pretransplant FEV1%x
0.60  0.19 .002
Postoperative
Interaction: double lung transplant
and lower post-transplant FEV1%
0.38  0.071 <.0001
Interaction: single lung transplant
and lower post-transplant FEV1%
2.3  0.24 <.0001
Propensity score 0.12  0.36 .7
SE, Standard error; FEV1%, forced 1-second expiratory volume (percentage of
predicted); NHANES, National Health and Nutrition Examination Survey.
*(Age/52)2, squared transformation. y(1/creatinine clearance), inverse transforma-
tion. zDouble lung transplant 3 [30/FEV1 (NHANES normalized)]. xSingle lung
transplant 3 [30/FEV1 (NHANES normalized)].
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Xobliterans syndrome (BOS), the most important cause of
mortality after lung transplantation.13 BOS reflects small
airway obliteration that results from chronic rejection,
with the histologic findings described as bronchiolitis oblit-
erans.14 Although post-transplant mortality is known to in-
crease after the development of BOS,15 the direct effect of
declining FEV1% on survival has not been described, and
statistical methods to investigate it have been lacking.
Therefore, we evaluated the longitudinal pattern ofThe Journal of Thoracic and CaFEV1% on post-transplant survival with a specific focus
on single versus double lung transplant.
Effect of FEV1% on Overall Post-Transplant
Mortality
We have shown that FEV1% peaks after both single and
double lung transplant at approximately 1 year. FEV1% af-
ter double lung transplant peaks at a higher level than after
single lung transplant, and this benefit endures at all meas-
urement points. As the FEV1% increases after transplanta-
tion, the risk of death decreases. Similarly, as FEV1%
declines, the risk of death increases. Although the risk fac-
tors for a decline in FEV1% after the onset of BOS have
been described, the relationship to survival has not.16 Addi-
tionally, the relationship of FEV1% on survival but inde-
pendent of BOS has not been demonstrated. The finding
that the risk of death varies inversely with FEV1% supports
its validity and highlights an important clinical observation.
In our study, the patients whose spirometry increased in the
first year after transplant demonstrated a survival advantage
during this period. This finding relates improving graft
function with better survival, and although intuitive, was
previously unproved. Similarly, as graft function declined,
survival worsened, even from relatively high FEV1%
levels. This suggests that regardless of the baseline level,
a downward trend in FEV1% is an ominous sign and
must be critically interrogated.
FEV1% and Single Versus Double Lung Transplant
The incremental improvement in spirometry of double
over single lung transplant seems relatively small and there-
fore calls into question its clinical value. However, werdiovascular Surgery c Volume 144, Number 1 201
Single LTx
Double LTx
FIGURE 4. Nomogram of multivariable equation presented in Table 2 il-
lustrating the relationship between forced 1-second expiratory volume
(FEV1% of predicted) at 5 years and survival after single or double lung
transplant (LTx). Values for other risk factors were set as follows: age,
49 years; no bronchiectasis or cystic fibrosis; donor creatinine, 0.9
mg/dL; pretransplant FEV1, 29% of predicted; propensity score, .5.
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Xfound a surprisingly strong benefit of double over single
lung transplant when considering the risk of death with
FEV1% decline. Although patients undergoing either sin-
gle or double lung transplant had substantially increased
risk of death when FEV1% decreased, the effect on double
lung transplant recipients was significantly tempered, sug-
gesting a protective effect of larger pulmonary reserve.
Some studies have suggested that double lung transplant
offers a protective effect against the development of BOS
compared with single lung transplant and a survival benefit
once BOS has developed.17 However, these findings are
subject to potential confounders, including that BOS is de-
fined as a percentage decline against a maximal baseline
value, and single lung transplant achieves a lower maximal
FEV1% value than double lung transplant. Thus, patients
receiving 2 lungs might be discriminated against and are
more likely to be classified as developing BOS than patients
receiving 1 lung.18 However, the design of our study re-
moves this confounder, evaluates the longitudinal trajectory
of FEV1%, and directly demonstrates the protective effect
of double lung transplant when the FEV1% declines. This
finding also highlights the important clinical finding that al-
though a declining FEV1% after both double and single
lung transplant is concerning, it is much more important af-
ter single lung transplant.Study Limitations
One limitation of the present study is that it represents the
clinical experience of a single transplant center. Addition-
ally, the main statistical analysis was conducted on the sub-
set of patients for whom the FEV1% measurements were
available, and the results might not be generalizable to the
target population of all lung transplant patients. Although202 The Journal of Thoracic and Cardiovascular Surgmeasurements were available for 82% of patients, those
who did not have spirometry data were ill and from the ear-
liest transplant era. However, given the relatively large ef-
fect of FEV1% in predicting death, it is likely that the
main conclusion of this analysis still holds qualitatively
for the target population.
A limitation of our analysis technique was that a 2-step
approach was required to relate patient-specific FEV1%
trajectory with survival. This trajectory was estimated
with a semiparametric smoothing method in the first step,
and the estimated trajectory was supplied to the multiphase
hazard model as a time-dependent covariable function in
the second step. This approach might have resulted in bias
in the coefficient estimates from the hazard model. How-
ever, because many patients have a large number of re-
peated FEV1% measurements, and the between-patient
variation in FEV1% is much larger than the within-
patient variation, we expect that the difference between
the estimated and true FEV1% trajectories was small and
did not lead to a large bias. A more formal analysis of these
types of data that properly adjusts for variation in the first
step and eliminates the bias is to jointly model the
FEV1% and survival data. Statistical methodology for
such a model is currently under development.
CONCLUSIONS
The choice of single versus double lung transplant con-
tinues to be debated from the perspective of survival, qual-
ity of life, and pulmonary function. However, we have
shown for the first time that changes in FEV1% after
lung transplantation are related to survival and that double
lung transplant appears to provide a survival benefit over
single lung transplant when FEV1% decreases, suggesting
a protective effect. This finding should be considered in
complex decision making when recommending lung trans-
plantation for a potential recipient as well as in postopera-
tive management.
The authors thank Kevin McCarthy, R-CPT, for providing pul-
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APPENDIX E1. BRIEF DESCRIPTION OF
TWO-STEP METHODOLOGY
The main purpose of our study was to assess and quantify
the relationship between postoperative forced 1-second ex-
piratory volume (FEV1%) and survival after lung trans-
plantation. Time zero is the time of transplantation, and
the FEV1% measurements are measured periodically after
transplant. Hence, the natural approach is to treat the post-
operative FEV1%measurements as a time-dependent cova-
riable function in a hazard model to assess the effect of
postoperative FEV1% on survival.
As seen in Figure 2, a parametric hazard model with con-
stant baseline hazard fits our time-to-death data well. Be-
cause of only a constant hazard, our multiphase hazard
model reduced to a ‘‘Cox-type’’ constant hazard model.
Suppose that YiðtÞ is the postoperative FEV1 measurement
for patient i at time t. Then, the ‘‘Cox-type’’ hazard model
can be written as
l

t; Yi

t
 ¼ l0ebYiðtÞ;
where l0 is the baseline constant hazard andYiðtÞ is the time-
dependent covariable. However, there is variability in the
postoperative longitudinal measurements of FEV1% owing
to measurement error and biologic variation. FEV1% is
a marker for pulmonary function, and there can be variation
in this marker over time owing to minor fluctuations in
health status and a number of sources of laboratorymeasure-
ment error, including variation among technicians, changes
in equipment, brands of laboratory kits, and repetition error.
Therefore, if one does not account for the variability due to
measurement error, the regression coefficient b in the hazard
model will be biased. To address this problem, several
authors have proposed different 2-step approaches.E1-E3
Simply speaking, the 2-step approach is as follows:
STEP 1:
Yi

t
 ¼ Yi

t
þεi;
where Yi ðtÞ is the true unobserved covariable value and εi is
a measurement error. We now estimate the true covariable
value at time t based on the observed longitudinal data up
to time t. We then use this estimated true covariable value
in step 2.
STEP 2:
l

t; Yi

t
 ¼ l0ebYi ðtÞ;
where b is the regression coefficient based on the true time-
dependent covariable Yi ðtÞ.
APPENDIX E2. VARIABLES USED IN THE
ANALYSES
Recipient variables
Demographic: Age (years), gender, race, weight (kg),
height (cm), body mass index (kg/m2), body sur-
face area (m2)
Diagnosis: Usual interstitial pneumonitis, chronic
obstructive pulmonary disease, cystic fibrosis,
a1-antitrypsin deficiency, pulmonary arterial
hypertension, sarcoidosis, bronchiectasis, Eisen-
menger syndrome, silicosis, other
Spirometry: Preoperative forced 1-second expiratory
volume (% of predicted) and series of postopera-
tive values
Comorbidities: Diabetes, creatinine (mg/dL)
Serology/immunology: Rhþ, blood type A, AB, B, O
Donor variables
Demographic: Age (years), gender, race, weight (kg),
height (cm), body mass index (kg/m2), body sur-
face area (m2)
History: Hypertension, creatinine (mg/dL)
Serology/immunology: Rhþ, blood type A, AB, B, O
Cause of death: Anoxia, cerebral bleeding, central ner-
vous system tumor, stroke, head trauma, other
Mismatch variables: Gender, Rhþ
Procedure: Maximum ischemic time (min), single or
double lung transplant
Experience: Date of operation
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FIGURE E1. Number of patients with spirometry measurements (forced
1-second expiratory volume, percentage of predicted [FEV1%]) available
at and beyond various time points and number of spirometry measurements
available for analysis.
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FIGURE E2. Mirrored histogram of distribution of propensity scores for
single lung transplant (LTx) (bars above zero line) and double lung trans-
plant (bars below zero line). Darkened area represents matched patient
pairs, showing that they cover the complete spectrum of cases.
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FIGURE E3. Covariable balance for some selected variables before and
after matching. Values in x-axis represent percentage of standardized dif-
ference* between single lung and double lung transplant groups. BMI,
Bodymass index;COD, cause of death;COPD, chronic obstructive pulmo-
nary disease; FEV1, forced 1-second expiratory volume; FVC, forced vital
capacity; LTx, lung transplant; Preop, preoperative. *Austin PC, Mamdani
MM. A comparison of propensity score methods: a case-study estimating
the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084–106.
TABLE E1. Recipient cause of death
Variable
Single LTx
(n ¼ 245)
Double LTx
(n ¼ 264)
P
value
Respiratory
Acute respiratory distress 3 (1.2) 2 (0.76) .6
Bronchiolitis 5 (2.0) 7 (2.7) .7
Graft failure 8 (3.3) 12 (4.5) .5
Respiratory failure 26 (11) 12 (4.5) .009
Respiratory hemorrhage 1 (0.41) 2 (0.76) .6
Pulmonary embolism 0 (0) 1 (0.38) .3
Other pulmonary 0 (0) 1 (0.38) .3
Infectious
Bacterial infection 17 (6.9) 7 (2.7) .02
Viral infection 3 (1.2) 4 (1.5) .8
Fungal infection 6 (2.4) 3 (1.1) .3
Cardiovascular
Cardiac arrest 5 (2.0) 2 (0.76) .2
Cardiogenic shock 1 (0.41) 0 (0) .3
Anoxia 1 (0.41) 1 (0.38) 1.0
Stroke 1 (0.41) 1 (0.38) 1.0
Other cerebral 1 (0.41) 0 (0) .3
Malignancy 15 (6.1) 6 (2.3) .03
Unknown 11 (4.5) 4 (1.5) .05
Data presented as n (%). LTx, Lung transplant.
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